SurvivorNet on MSN
New lung cancer drug, Ivonescimab, showed promising results in major HARMONi-6 trial, but US patients will need to wait for HARMONi-3 update
A new drug called ivonescimab just beat standard immunotherapy in a major lung cancer trial: patients lived nearly four ...
Morning Overview on MSN
A bispecific antibody beat a standard immunotherapy regimen head-to-head in squamous lung cancer at ASCO 2026
A bispecific antibody that simultaneously targets PD-1 and VEGF extended overall survival by more than four months compared ...
Despite recent advances in immunotherapy and targeted therapy, most patients with non-small-cell lung cancer (NSCLC) continue to have disease progression and develop resistance to current treatments.
Analysts, investors and partner Summit Therapeutics had all been keenly awaiting the overall survival update, after previous ...
It’s the moment of truth for Akeso’s ivonescimab, and to many, a high-stakes test for China’s booming biotech industry. | ...
9don MSN
A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China
An experimental lung cancer drug from Akeso and Summit Therapeutics reduced the risk of death by 34% in a late-stage trial, ...
GlobalData on MSN
ASCO26: key readouts in lung cancer
At ASCO 2026, companies debuted data that could hold the potential to disrupt the frontline treatment paradigm for various ...
A lung cancer drug developed in China was a highlight of ASCO but doctors want to see follow-up in a more diverse population.
New dual-action drug a ‘promising step forward’ for patients with hard-to-treat lung cancer - Experts have described the ...
A lung cancer drug reduced the risk of death by 34% in a late-stage trial, in the latest sign of China’s pharmaceutical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results